Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.
作者信息
Castillo Jorge J, Gustine Joshua N, Meid Kirsten, Dubeau Toni, Severns Patricia, Treon Steven P
机构信息
Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA, USA
Harvard Medical School, Boston, MA, USA.
出版信息
Haematologica. 2018 Jul;103(7):e307-e310. doi: 10.3324/haematol.2017.186908. Epub 2018 Feb 22.
Abstract
摘要
相似文献
1
Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia.华氏巨球蛋白血症患者的依鲁替尼撤药症状。
Haematologica. 2018 Jul;103(7):e307-e310. doi: 10.3324/haematol.2017.186908. Epub 2018 Feb 22.
2
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼可能对新冠病毒感染患者的肺损伤具有保护作用。
Blood. 2020 May 21;135(21):1912-1915. doi: 10.1182/blood.2020006288.
3
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.依鲁替尼可穿透血脑屏障，在治疗宾尼尔综合征方面显示出疗效。
Br J Haematol. 2017 Oct;179(2):339-341. doi: 10.1111/bjh.14218. Epub 2016 Jul 13.
4
Efficacy of ibrutinib in the treatment of Bing-Neel syndrome.依鲁替尼治疗宾-尼尔综合征的疗效。
Am J Hematol. 2016 Mar;91(3):E17-9. doi: 10.1002/ajh.24279.
5
Zanubrutinib for the treatment of Waldenström Macroglobulinemia.泽布替尼用于治疗华氏巨球蛋白血症。
Expert Rev Hematol. 2020 Dec;13(12):1303-1310. doi: 10.1080/17474086.2020.1851184. Epub 2020 Dec 9.
6
Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib.伊布替尼治疗华氏巨球蛋白血症相关自身免疫性溶血的疗效
J Oncol Pract. 2016 May;12(5):490-1. doi: 10.1200/JOP.2016.011932.
7
Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.伊布替尼单药治疗 Waldenström 巨球蛋白血症的临床试验之外的应用：实践模式、毒性和结果。
Br J Haematol. 2020 Feb;188(3):394-403. doi: 10.1111/bjh.16168. Epub 2019 Aug 29.
8
Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report.伊布替尼治疗华氏巨球蛋白血症并发症宾-尼尔综合征：病例报告
J Oncol Pharm Pract. 2019 Sep;25(6):1534-1539. doi: 10.1177/1078155219830162. Epub 2019 Feb 13.
9
Ibrutinib in the management of Waldenstrom macroglobulinemia.伊布替尼用于治疗华氏巨球蛋白血症
J Oncol Pharm Pract. 2019 Mar;25(2):434-441. doi: 10.1177/1078155218786037. Epub 2018 Jul 12.
10
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.在华氏巨球蛋白血症患者中，CXCL13水平升高，且可预测对伊布替尼的主要反应。
Haematologica. 2017 Nov;102(11):e452-e455. doi: 10.3324/haematol.2017.172627. Epub 2017 Aug 10.
引用本文的文献
1
Six-year follow-up of phase II study exploring chemo-free treatment association with idelalisib and obinutuzumab in symptomatic relapsed/ refractory patients with Waldenström's macroglobulinemia.探索idelalisib和奥滨尤妥珠单抗联合无化疗治疗有症状的复发/难治性华氏巨球蛋白血症患者的II期研究的六年随访
Ann Hematol. 2025 Jan;104(1):685-690. doi: 10.1007/s00277-024-06076-1. Epub 2024 Nov 5.
2
How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.我如何在 Waldenström 巨球蛋白血症的治疗中使用基因组学和 BTK 抑制剂。
Blood. 2024 Apr 25;143(17):1702-1712. doi: 10.1182/blood.2022017235.
3
Waldenström Macroglobulinemia: Targeted Agents Taking Center Stage.华氏巨球蛋白血症：靶向药物占据舞台中心。
Drugs. 2024 Jan;84(1):17-25. doi: 10.1007/s40265-023-01974-6. Epub 2023 Dec 6.
4
A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients.硼替佐米联合沙利度胺治疗初治华氏巨球蛋白血症的 II 期研究。
Cancer Res Treat. 2024 Apr;56(2):675-680. doi: 10.4143/crt.2023.681. Epub 2023 Sep 25.
5
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia.布鲁顿酪氨酸激酶抑制剂在华氏巨球蛋白血症治疗中的应用。
Am J Hematol. 2023 Feb;98(2):338-347. doi: 10.1002/ajh.26788. Epub 2023 Jan 1.
6
An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation.一位 81 岁男性，患有慢性淋巴细胞白血病 6 年，在停用伊布替尼后疾病复发。
Am J Case Rep. 2022 Aug 26;23:e935941. doi: 10.12659/AJCR.935941.
7
Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes and Evaluation.华氏巨球蛋白血症出血倾向：潜在原因与评估。
Thromb Haemost. 2022 Nov;122(11):1843-1857. doi: 10.1055/a-1896-7092. Epub 2022 Jul 11.
8
Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.替拉鲁替尼单药治疗巨球蛋白血症的 2 年结果。
Cancer Sci. 2022 Jun;113(6):2085-2096. doi: 10.1111/cas.15344. Epub 2022 Apr 6.
9
Treatment options for relapsed Waldenström's Macroglobulinemia.复发型华氏巨球蛋白血症的治疗选择。
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000221. eCollection 2019 Jun.
10
The Care of the Leukemic Patients in Times of SARS-CoV-2.SARS-CoV-2 流行时期的白血病患者护理。
Curr Oncol Rep. 2021 Aug 3;23(10):114. doi: 10.1007/s11912-021-01111-0.
本文引用的文献
1
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia.依鲁替尼剂量强度对既往治疗的华氏巨球蛋白血症患者预后的影响。
Haematologica. 2018 Oct;103(10):e466-e468. doi: 10.3324/haematol.2018.191999. Epub 2018 May 17.
2
CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib.在华氏巨球蛋白血症患者中，CXCL13水平升高，且可预测对伊布替尼的主要反应。
Haematologica. 2017 Nov;102(11):e452-e455. doi: 10.3324/haematol.2017.172627. Epub 2017 Aug 10.
3
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.布鲁顿酪氨酸激酶抑制剂依鲁替尼通过调节肿瘤浸润巨噬细胞发挥免疫调节作用。
Oncotarget. 2017 Jun 13;8(24):39218-39229. doi: 10.18632/oncotarget.16836.
4
How I manage ibrutinib-refractory chronic lymphocytic leukemia.我如何治疗依鲁替尼难治性慢性淋巴细胞白血病。
Blood. 2017 Mar 9;129(10):1270-1274. doi: 10.1182/blood-2016-09-693598. Epub 2017 Jan 17.
5
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.伊布替尼治疗利妥昔单抗难治性华氏巨球蛋白血症患者（iNNOVATE）：一项国际多中心 3 期临床试验的开放性亚研究。
Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.
6
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.伊布替尼治疗华氏巨球蛋白血症：最新证据与临床经验
Ther Adv Hematol. 2016 Aug;7(4):179-86. doi: 10.1177/2040620716654102. Epub 2016 Jun 13.
7
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.依鲁替尼对体内慢性淋巴细胞白血病肿瘤微环境相互作用的破坏——一项研究者发起的II期研究结果
Clin Cancer Res. 2016 Apr 1;22(7):1572-82. doi: 10.1158/1078-0432.CCR-15-1965. Epub 2015 Dec 9.
8
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.布鲁顿酪氨酸激酶（Btk）抑制剂依鲁替尼对单核细胞Fcγ受体（FcγR）功能的影响分析
J Biol Chem. 2016 Feb 5;291(6):3043-52. doi: 10.1074/jbc.M115.687251. Epub 2015 Dec 1.
9
Ibrutinib in previously treated Waldenström's macroglobulinemia.伊布替尼治疗既往治疗的华氏巨球蛋白血症。
N Engl J Med. 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548.
10
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.华氏巨球蛋白血症启动治疗的预后标志物和标准：第二届华氏巨球蛋白血症国际研讨会共识小组建议
Semin Oncol. 2003 Apr;30(2):116-20. doi: 10.1053/sonc.2003.50038.
Zotero 插件